K2 Therapeutics Named One of 2026 Endpoints 11

BOSTON and SINGAPORE, Sept. 25, 2026 /CourierPR/ -- K2 Therapeutics, a biotechnology company built for global impact, has been named one of the 2026 Endpoints 11 by Endpoints News. This annual recognition honors the most promising private biotech companies, celebrating those that are challenging conventional thinking and pursuing transformative opportunities.

Founded by MPM BioImpact in 2024, K2 Therapeutics is at the forefront of biotechnology innovation. The company combines worldwide asset sourcing and experienced drug development leadership to identify and advance high-potential first-in-class and best-in-class therapeutic candidates. Currently, K2's diversified portfolio includes eight therapeutic programs across multiple modalities, such as antibody-drug conjugates and T-cell engagers.

In August 2026, K2 announced a significant $50 million in seed financing from MPM BioImpact. This funding will support the company's continued pursuit of groundbreaking therapeutic candidates and its vision to build a pipeline focused on high-potential first- and best-in-class assets with meaningful potential for patient impact worldwide.

K2 Therapeutics aims to build a company that is unconstrained by modality or geography, identifying the world's most innovative assets and translating them into great medicines through a disciplined development approach led by experienced drug developers. The company's commitment to global impact and transformative innovation is evident in its recognition as one of the 2026 Endpoints 11.